Клопидогрель в клинической практике при реваскуляризации миокарда: от истоков к последним рекомендациям

Клопидогрель в клинической практике при реваскуляризации миокарда: от истоков к последним рекомендациям

Автор: И.О. Гражданкин, В.И. Байструков, Е.И. Кретов, А.М. Чернявский

Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin

Рубрика: Обзоры

Статья в выпуске: 1 т.26, 2022 года.

Бесплатный доступ

Ишемическая болезнь сердца — одна из главных причин смертности и инвалидизации населения. Важнейший компонент комплексной терапии атеросклероза — реваскуляризация миокарда. Клопидогрель благодаря приемлемым для клинической практики свойствам долгое время используют в антитромбоцитарной терапии. Наибольшая доказательная база среди всех ингибиторов P2Y12-рецепторов тромбоцитов позволяет применять его как в рядовых, так и в сложных клинических ситуациях. Особенности фармакокинетики и фармакодинамики препарата влияют на его использование. Современные рекомендации определяют место и роль клопидогреля в лечении больных до и после реваскуляризации. В статье рассмотрены различные аспекты антиагрегантной терапии с учетом рисков пациента на основании европейских рекомендаций по лечению больных острым и хроническим коронарным синдромом.

Еще

Двойная антитромбоцитарная терапия, деэскалационный подход, клопидогрель, острый коронарный синдром, реваскуляризация миокарда, риск кровотечения

Короткий адрес: https://sciup.org/142231150

IDR: 142231150   |   DOI: 10.21688/1681-3472-2022-1-32-43

Список литературы Клопидогрель в клинической практике при реваскуляризации миокарда: от истоков к последним рекомендациям

  • Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., Herbert J.M. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891-896. PMID: 11127873.
  • Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N.A., Okazaki O., Ikeda T., Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38(1):92-99. PMID: 19812348. https://doi.org/10.1124/dmd.109.029132
  • Scott S.A., Sangkuhl K., Shuldiner A.R., Hulot J.-S., Thorn C.F., Altman R.B., Klein T.E. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159-165. PMID: 22027650; PMCID: PMC3349992. https://doi.org/10.1097/FPC.0b013e32834d4962
  • Scott S.A., Sangkuhl K., Gardner E.E., Stein C.M., Hulot J.-S., Johnson J.A., Roden D.M., Klein T.E., Shuldiner A.R., Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328-332. PMID: 21716271; PMCID: PMC3234301. https://doi.org/10.1038/clpt.2011.132
  • Кукес В.Г., Сычев Д.А., Раменская Г.В., Игнатьев И.В. Фармакогенетика системы биотрансформации и транспортеров лекарственных средств: от теории к практике. Биомедицина. 2007;1(1):29-47. [Kukes V.G., Sychev D.A., Ramenskaja G.V., Ignat'ev I.V. Pharmacogenetics of system of biotransformation and drugs transporters: from theory to practice. Journal Biomed. 2007;1(1):29-47. (In Russ.)]
  • Galeazzi R., Olivieri F., Spazzafumo L., Rose G., Montesanto A., Giovagnetti S., Cecchini S., Malatesta G., Di Pillo R., Antonicelli R. Clustering of ABCB1 and CYP2C19 genetic variants predicts risk of major bleeding and thrombotic events in elderly patients with acute coronary syndrome receiving dual antiplatelet therapy with aspirin and clopidogrel. Drugs Aging. 2018;35(7):649-656. PMID: 29936693; PMCID: PMC6061429. https://doi.org/10.1007/s40266-018-0555-1
  • Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J., Morath T., Schömig A., von Beckerath N., Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512-518. PMID: 20083681. https://doi.org/10.1161/CIRCULATIONAHA.109.885194
  • Grosdidier C., Quilici J., Loosveld M., Camoin L., Moro P.J., Saut N., Gaborit B., Pankert M., Cohen W., Lambert M., Beguin Sh., Morange P.E., Bonnet J.-L., Alessi M.-C., Cuisset T. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol. 2013;111(7):985-990. PMID: 23340030. https://doi.org/10.1016/j.amjcard.2012.12.013
  • Huang B., Cui D.-J., Ren Y., Han B., Yang D.-P., Zhao X. Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis. J Res Med Sci. 2017;22:109. PMID: 29026425; PMCID: PMC5629834. https://doi.org/10.4103/jrms.JRMS_590_16
  • Trenk D., Hochholzer W., Fromm M.F., Chialda L.-E., Pahl A., Valina C.M., Stratz C., Schmiebusch P., Bestehorn H.-P., Büttner H.J., Neumann F.-J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-1934. PMID: 18482659. https://doi.org/10.1016/j.jacc.2007.12.056
  • Mega J.L., Close S.L., Wiviott S.D., Shen L., Walker J.R., Simon T., Antman E.M., Braunwald E., Sabatine M.S. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312-1319. PMID: 20801494; PMCID: PMC3036672. https://doi.org/10.1016/S0140-6736(10)61273-1
  • Collet J.-P., Hulot J.-S., Pena A., Villard E., Esteve J.-B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317. PMID: 19108880. https://doi.org/10.1016/S0140-6736(08)61845-0
  • Price M.J., Berger P.B., Teirstein P.S., Tanguay J.-F., Angiolillo D.J., Spriggs D., Puri S., Robbins M., Garratt K.N., Bertrand O.F., Stillabower M.E., Aragon J.R., Kandzari D.E., Stinis C.T., Lee M.S., Manoukian S.V., Cannon C.P., Schork N.J., Topol E.J., GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-1105. PMID: 21406646. https://doi.org/10.1001/jama.2011.290
  • Cavallari L.H., Lee C.R., Beitelshees A.L., Cooper-DeHoff R.M., Duarte J.D., Voora D., Kimmel S.E., McDonough C.W., Gong Y., Dave C.V., Pratt V.M., Alestock T.D., Anderson R.D., Alsip J., Ardati A.K., Brott B.C., Brown L., Chumnumwat S., Clare-Salzler M.J., Coons J.C., Denny J.C., Dillon C., Elsey A.R., Hamadeh I.S., Harada Sh., Hillegass W.B., Hines L., Horenstein R.B., Howell L.A., Jeng L.J.B., Kelemen M.D., Lee Y.M., Magvanjav O., Montasser M., Nelson D.R., Nutescu E.A., Nwaba D.C., Pakyz R.E., Palmer K., Peterson J.F., Pollin T.I., Quinn A.H., Robinson Sh.W., Schub J., Skaar T.C., Smith D.M., Sriramoju V.B., Starostik P., Stys T.P., Stevenson J.M., Varunok N., Vesely M.R., Wake D.T., Weck K.E., Weitzel K.W., Wilke R.A., Willig J., Zhao R.Y., Kreutz R.P., Stouffer G.A., Empey P.E., Limdi N.A., Shuldiner A.R., Winterstein A.G., Johnson J.A., IGNITE Network. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018;11(2):181-191. PMID: 29102571; PMCID: PMC5775044. https://doi.org/10.1016/j.jcin.2017.07.022
  • Holmes M.V., Perel P., Shah T., Hingorani A.D., Casas J.P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704-2714. PMID: 22203539. https://doi.org/10.1001/jama.2011.1880
  • Bergmeijer T.O., Janssen P.W.A., Schipper J.C., Qaderdan K., Ishak M., Ruitenbeek R.S., Asselbergs F.W., van 't Hof A.W.J., Dewilde W.J.M., Spanó F., Herrman J.-P.R., Kelder J.C., Postma M.J., de Boer A., Deneer V.H.M., ten Berg J.M. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients–Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J. 2014;168(1):16-22.e1. PMID: 24952855. https://doi.org/10.1016/j.ahj.2014.03.006
  • Claassens D.M.F., Vos G.J.A., Bergmeijer T.O., Hermanides R.S., van 't Hof A.W.J., van der Harst P., Barbato E., Morisco C., Tjon Joe Gin R.M., Asselbergs F.W., Mosterd A., Herrman J.-P.R., Dewilde W.J.M., Janssen P.W.A., Kelder J.C., Postma M.J., de Boer A., Boersma C., Deneer V.H.M., Ten Berg J.M. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621-1631. PMID: 31479209. https://doi.org/10.1056/NEJMoa1907096
  • Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., Hindricks G., Kastrati A., Lenzen M.J., Prescott E., Roffi M., Valgimigli M., Varenhorst C., Vranckx P., Widimský P., ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. PMID: 28886621. https://doi.org/10.1093/eurheartj/ehx393
  • Dworeck C., Redfors B., Angerås O., Harald¬sson I., Odenstedt J., Ioanes D., Petursson P., Völz S., Persson J., Koul S., Venetsanos D., Ulvenstam A., Hofmann R., Jensen J., Albertsson P., Råmunddal T., Jeppsson A., Erlinge D., Omerovic E. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA Netw Open. 2020;3(10):e2018735. PMID: 33001202; PMCID: PMC7530628. https://doi.org/10.1001/jamanetworkopen.2020.18735
  • Ferguson J.J. Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibrinolytic therapy — CLARITY-TIMI 28. Future Cardiol. 2005;1(5):605-610. PMID: 19804099. https://doi.org/10.2217/14796678.1.5.605
  • Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Collins R., Liu L.S., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-1621. PMID: 16271642. https://doi.org/10.1016/S0140-6736(05)67660-X
  • Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A., Jüni P., Kastrati A., Kolh P., Mauri L., Montalescot G., Neumann F.-J., Petricevic M., Roffi M., Steg P.G., Windecker S., Zamorano J.L., Levine G.N., ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. PMID: 28886622. https://doi.org/10.1093/eurheartj/ehx419
  • Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., Copland I., Fox K.A., Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533. PMID: 11520521. https://doi.org/10.1016/s0140-6736(01)05701-4
  • Mehta S.R., Tanguay J.-F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B., Faxon D.P., Rupprecht H.-J., Budaj A., Avezum A., Widimsky P., Steg P.G., Bassand J.-P., Montalescot G., Macaya C., Di Pasquale G., Niemela K., Ajani A.E., White H.D., Chrolavicius S., Gao P., Fox K.A.A., Yusuf S., CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-1243. PMID: 20817281. https://doi.org/10.1016/S0140-6736(10)61088-4
  • Collet J.-P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L., Dendale P., Dorobantu M., Edvardsen T., Folliguet T., Gale C.P., Gilard M., Jobs A., Jüni P., Lambrinou E., Lewis B.S., Mehilli J., Meliga E., Merkely B., Mueller C., Roffi M., Rutten F.H., Sibbing D., Siontis G.C.M., ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. PMID: 32860058. https://doi.org/10.1093/eurheartj/ehaa575
  • Yeh R.W., Secemsky E.A., Kereiakes D.J., Normand S.-L., Gershlick A.H., Cohen D.J., Spertus J.A., Steg P.G., Cutlip D.E., Rinaldi M.J., Camenzind E., Wijns W., Apruzzese P.K., Song Y., Massaro J.M., Mauri L., DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735-1749. PMID: 27022822; PMCID: PMC5408574. https://doi.org/10.1001/jama.2016.3775
  • Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G., Normand S.-L.T., Braunwald E., Wiviott S.D., Cohen D.J., Holmes D.R. Jr., Krucoff M.W., Hermiller J., Dauerman H.L., Simon D.I., Kandzari D.E., Garratt K.N., Lee D.P., Pow T.K., Ver Lee P., Rinaldi M.J., Massaro J.M., DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166. PMID: 25399658; PMCID: PMC4481318. https://doi.org/10.1056/NEJMoa1409312
  • Stefanescu Schmidt A.C., Kereiakes D.J., Cutlip D.E., Yeh R.W., D'Agostino R.B. Sr., Massaro J.M., Hsieh W.-H., Mauri L., DAPT Investigators. Myocardial infarction risk after discontinuation of thienopyridine therapy in the randomized DAPT study (Dual AntiPlatelet Therapy). Circulation. 2017;135(18):1720-1732. PMID: 28228427; PMCID: PMC5469374. https://doi.org/10.1161/CIRCULATIONAHA.116.024835
  • Mega J.L., Braunwald E., Wiviott S.D., Bassand J.-P., Bhatt D.L., Bode C., Burton P., Cohen M., Cook-Bruns N., Fox K.A.A., Goto Sh., Murphy S.A., Plotnikov A.N., Schneider D., Sun X., Verheugt F.W.A., Gibson C.M.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19. PMID: 22077192. https://doi.org/10.1056/NEJMoa1112277
  • Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., Harrington R.A. PLATO Investigators, Freij A., Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057. PMID: 19717846. https://doi.org/10.1056/NEJMoa0904327
  • Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb Sh., Neumann F.-J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. PMID: 17982182. https://doi.org/10.1056/NEJMoa0706482
  • Jinnouchi H., Mori H., Cheng Q., Kutyna M., Torii Sh., Sakamoto A., Guo L., Acampado E., Gupta A., Kolodgie F.D., Virmani R., Finn A.V. Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy. EuroIntervention. 2019;15(4):e342-e353. PMID: 30375338. https://doi.org/10.4244/EIJ-D-18-00740
  • Räber L., Mintz G.S., Koskinas K.C., Johnson T.W., Holm N.R., Onuma Y., Radu M.D., Joner M., Yu B., Jia H., Meneveau N., de la Torre Hernandez J.M., Escaned J., Hill J., Prati F., Colombo A., di Mario C., Regar E., Capodanno D., Wijns W., Byrne R.A., Guagliumi G., ESC Scientific Document Group. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018;39(35):3281-3300. PMID: 29790954. Erratum in: Eur Heart J. 2019;40(3):308. https://doi.org/10.1093/eurheartj/ehy285
  • Hahn J.-Y., Song Y.B., Oh J.-H., Cho D.-K., Lee J.B., Doh J.-H., Kim S.-H., Jeong J.-O., Bae J.-H., Kim B.-O., Cho J.H., Suh I.-W., Kim D.-I., Park H.-K., Park J.-S., Choi W.G., Lee W.S., Kim J., Choi K.H., Park T.K., Lee J.M., Yang J.H., Choi J.-H., Choi S.-H., Gwon H.-C., SMART-DATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274-1284. PMID: 29544699. https://doi.org/10.1016/S0140-6736(18)30493-8
  • Hahn J.-Y., Song Y.B., Oh J.-H., Chun W.J., Park Y.H., Jang W.J., Im E.-S., Jeong J.-O., Cho B.R., Oh S.K., Yun K.H., Cho D.-K., Lee J.-Y., Koh Y.-Y., Bae J.-W., Choi J.W., Lee W.S., Yoon H.J., Lee S.U., Cho J.H., Choi W.G., Rha S.-W., Lee J.M., Park T.K., Yang J.H., Choi J.-H., Choi S.-H., Lee S.H., Gwon H.-Ch., SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428-2437. PMID: 31237645; PMCID: PMC6593635. https://doi.org/10.1001/jama.2019.8146
  • Vranckx P., Valgimigli M., Juni P., Hamm C., Steg P.G., Heg D., van Es G.A., McFadden E.P., Onuma Y., van Meijeren C., Chichareon P., Benit E., Mollmann H., Janssens L., Ferrario M., Moschovitis A., Zurakowski A., Dominici M., Van Geuns R.J., Huber K., Slagboom T., Serruys P.W., Windecker S., GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940-949. PMID: 30166073. https://doi.org/10.1016/S0140-6736(18)31858-0
  • Kim B.-K., Hong S.-J., Cho Y.-H., Yun K.H., Kim Y.H., Suh Y., Cho J.Y., Her A.-Y., Cho S., Jeon D.W., Yoo S.-Y., Cho D.-K., Hong B.-K., Kwon H., Ahn Ch.-M., Shin D.-H., Nam Ch.-M., Kim J.-S., Ko Y.-G., Choi D., Hong M.-K., Jang Y., TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407-2416. PMID: 32543684; PMCID: PMC7298605. https://doi.org/10.1001/jama.2020.7580
  • Mehran R., Baber U., Sharma S.K., Cohen D.J., Angiolillo D.J., Briguori C., Cha J.Y., Collier T., Dangas G., Dudek D., Džavík V., Escaned J., Gil R., Gurbel P., Hamm C.W., Henry T., Huber K., Kastrati A., Kaul U., Kornowski R., Krucoff M., Kunadian V., Marx S.O., Mehta Sh.R., Moliterno D., Ohman E.M., Oldroyd K., Sardella G., Sartori S., Shlofmitz R., Steg P.G., Weisz G., Witzenbichler B., Han Y.-L., Pocock S., Gibson C.M. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032-2042. PMID: 31556978. https://doi.org/10.1056/NEJMoa1908419
  • Zettler M.E., Peterson E.D., McCoy L.A., Effron M.B., Anstrom K.J., Henry T.D., Baker B.A., Messenger J.C., Cohen D.J., Wang T.Y., TRANSLATE-ACS Investigators. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62-68. PMID: 27979043. https://doi.org/10.1016/j.ahj.2016.10.006
  • Angiolillo D.J., Rollini F., Storey R.F., Bhatt D.L., James S., Schneider D.J., Sibbing D., So D.Y.F., Trenk D., Alexopoulos D., Gurbel P.A., Hochholzer W., De Luca L., Bonello L., Aradi D., Cuisset T., Tantry U.S., Wang T.Y., Valgimigli M., Waksman R., Mehran R., Montalescot G., Franchi F., Price M.J. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136(20):1955-1975. PMID: 29084738. https://doi.org/10.1161/CIRCULATIONAHA.117.031164
  • Sibbing D., Aradi D., Jacobshagen C., Gross L., Trenk D., Geisler T., Orban M., Hadamitzky M., Merkely B., Kiss R.G., Komócsi A., Dézsi C.A., Holdt L., Felix S.B., Parma R., Klopotowski M., Schwinger R.H.G., Rieber J., Huber K., Neumann F.-J., Koltowski L., Mehilli J., Huczek Z., Massberg S., TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747-1757. PMID: 28855078. https://doi.org/10.1016/S0140-6736(17)32155-4
  • Pereira N.L., Farkouh M.E., So D., Lennon R., Geller N., Mathew V., Bell M., Bae J.-H., Jeong M.H., Chavez I., Gordon P., Abbott J.D., Cagin Ch., Baudhuin L., Fu Y.-P., Goodman Sh.G., Hasan A., Iturriaga E., Lerman A., Sidhu M., Tanguay J.-F., Wang L., Weinshilboum R., Welsh R., Rosenberg Y., Bailey K., Rihal Ch. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761-771. PMID: 32840598; PMCID: PMC7448831. https://doi.org/10.1001/jama.2020.12443
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp